Augmented pressor and sympathetic responses to skeletal muscle metaboreflex activation in type 2 diabetes patients

Seth W. Holwerda, Robert M. Restaino, Camila Manrique, Guido Lastra, James P. Fisher, Paul J. Fadel

1Department of Medical Pharmacology and Physiology, 2Department of Medicine, 3Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, 4School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK

Running Title: augmented metaboreflex activation in T2D

Keywords: exercise, hypertension, muscle sympathetic nerve activity, post exercise ischemia, blood pressure

Correspondence:
Paul J. Fadel, PhD
Department of Kinesiology
College of Nursing and Health Innovation
University of Texas at Arlington
500 W. Nedderman #115, Arlington, TX 76019
1-817-272-3288
fadelp@uta.edu

Copyright © 2015 by the American Physiological Society.
ABSTRACT

Previous studies have reported exaggerated increases in arterial blood pressure during exercise in type 2 diabetes (T2D) patients. However, little is known regarding the underlying neural mechanism(s) involved. We hypothesized that T2D patients would exhibit an augmented muscle metaboreflex activation and this contributes to greater pressor and sympathetic responses during exercise. Mean arterial pressure (MAP), heart rate (HR), and muscle sympathetic nerve activity (MSNA) were measured in 16 patients with T2D (8 normotensive and 8 hypertensive) and 10 healthy controls. Graded isolation of the muscle metaboreflex was achieved by post-exercise ischemia (PEI) following static handgrip performed at 30% and 40% maximal voluntary contraction (MVC). A cold pressor test (CPT) was also performed as a generalized sympathoexcitatory stimulus. Increases in MAP and MSNA during 30 and 40% MVC handgrip were augmented in T2D patients compared to controls (P<0.05), and these differences were maintained during PEI (MAP: 30% PEI: T2D, Δ16 ± 2 vs. Controls, Δ8 ± 1 mmHg; 40% PEI: T2D, Δ26 ± 3 vs. Controls, Δ16 ± 2 mmHg, both P<0.05). MAP and MSNA responses to handgrip and PEI were not different between normotensive and hypertensive T2D patients (P>0.05). Interestingly, MSNA responses were also greater in T2D patients compared to controls during the CPT (P<0.05). Collectively, these findings indicate that muscle metaboreflex activation is augmented in T2D patients and this contributes, in part, to augmented pressor and sympathetic responses to exercise in this patient group. Greater CPT responses suggest that a heightened central sympathetic reactivity may be involved.
Muscle metaboreflex activation is augmented in type 2 diabetic patients, and this contributes, in part, to augmented pressor and sympathetic responses to exercise in this patient group. These findings provide important insight to the neural mechanisms that contribute to the exaggerated increases in exercise blood pressure in type 2 diabetes.
INTRODUCTION

Type 2 diabetes patients (T2D) exhibit exaggerated increases in arterial blood pressure (BP) during exercise (23, 25, 39, 44). Augmented BP responses have been observed even during moderate intensity handgrip (38), a level of isometric forearm muscle contraction that is equivalent to many activities of daily living such as opening jars, or carrying groceries. This is important because repeated surges in BP throughout the day have been related to increased cardiovascular risk (11, 37). Likewise, exaggerated increases in exercise BP are related to adverse cardiovascular and cerebrovascular events both during and after physical activity (19, 27, 33). Indeed, the incidence of cardiovascular and cerebrovascular events such as myocardial infarction and stroke are significantly elevated among T2D patients (5, 26, 28, 57). An augmented pressor response to exercise is also a predictor for the development of hypertension (HTN) (10, 47), a common comorbidity among T2D patients (1, 3, 49, 50). However, despite exaggerated BP responses to exercise and the associated increase in morbidity and mortality in T2D, little is known regarding the underlying neural mechanism(s) involved.

Exercise evokes increases in BP, muscle sympathetic nerve activity (MSNA), and heart rate (HR) that are a result of an integration of central signals originating from higher brain centers (i.e., central command) (15), feedback signals from mechanically and metabolically sensitive afferents in contracting skeletal muscle (i.e., exercise pressor reflex; EPR) (2), and input from the arterial and cardiopulmonary baroreceptors (14, 21). During static handgrip exercise, central command increases heart rate and cardiac output by withdrawing parasympathetic tone (15), whereas the metabolic component of the EPR (i.e., muscle metaboreflex) is primarily responsible for the intensity-dependent increase in MSNA and peripheral vasoconstriction (30, 45). A number of studies have examined the muscle
metaboreflex in subjects with risk factors for T2D (e.g., obesity) and have yielded mixed results
(9, 29, 35, 40, 41, 52). Surprisingly, there is a paucity of studies examining the muscle
metaboreflex in subjects with overt T2D. Furthermore, no studies have examined whether
muscle metaboreflex activation in T2D leads to excessive MSNA responses that could contribute
to an exaggerated EPR. A focus on the regulatory mechanisms underlying the augmented neural
cardiovascular responses to exercise in T2D is important and clinically relevant.

Given the vital contribution of the muscle metaboreflex to the BP response to exercise,
and the previous work demonstrating exaggerated BP responses to exercise in T2D patients, the
purpose of this study was to test the hypothesis that BP and MSNA responses to muscle
metaboreflex activation would be greater in T2D patients compared to healthy control subjects.
Additionally, because T2D is commonly associated with HTN, and previous work has shown
that the muscle metaboreflex is augmented with HTN (9, 34, 41), we also hypothesized that
muscle metaboreflex activation would be further enhanced in T2D patients with HTN. To test
these hypotheses, BP, MSNA, and HR were measured during graded isolation of the muscle
metaboreflex using post-exercise ischemia (PEI) following static handgrip performed at 30% and
40% maximal voluntary contraction (MVC). PEI was used to trap local metabolites produced
during exercise and isolate activation of metabolically sensitive skeletal muscle afferent nerve
endings from the mechanical component of the EPR and central command (2, 30). A cold
pressor test (CPT) was also performed to quantify BP and MSNA responses to a generalized
non-exercise sympatho-excitatory stimulus.
Methods

Subjects. A total of 27 subjects participated in the present study: Sixteen patients with T2D (reported duration of disease: 8 ± 2 years) and 10 healthy controls matched to T2D patients for age, sex and body weight. General baseline characteristics of the T2D patients and healthy control subjects are provided in Table 1. Eight of the T2D patients also had a clinical diagnosis of hypertension. These patients were all being treated for their hypertension but we excluded any patients taking medications directly influencing MSNA (e.g., central sympathoinhibitors such as clonidine). A listing of the medications being taken by the T2D patients is provided in Table 2. Importantly, none of the T2D patients were being treated for or had symptoms of peripheral neuropathy. Table 3 provides a comparison of baseline characteristics between the T2D patients with and without hypertension. Each subject received a verbal and written explanation of the goals of the study, the experimental measurements, and risks and benefits associated with the study after which each subject provided written informed consent. All subjects also completed a medical health history questionnaire and a 12-h fasting blood chemistry screening including a lipid panel and a metabolic panel that also includes insulin, glucose, and HbA1c measurement. The experimental procedures and protocols used conformed to the Declaration of Helsinki and were approved by the University of Missouri Health Sciences Institutional Review Board.

Cardiovascular and Metabolic Measurements. HR and BP were continuously monitored using a lead II surface ECG (Q710; Quinton, Bothell, WA, USA) and a servo-controlled finger photoplethysmography (Finometer; Finapres Medical Systems, Amsterdam, The Netherlands), respectively. For Finometer measurements, return to flow calibrations were performed and
physiological turned off before each recording. The changes in BP measured using the Finometer have been shown to provide an accurate estimate of directly measured intra-arterial BP (18, 46). Also, an automated sphygmomanometer (Welch Allyn, Skaneateles Falls, NY) recorded resting BP by the auscultation of the brachial artery of the right arm for absolute values of BP and to validate BP measurements from the Finometer (7, 54). Respiratory movements were monitored using a strain-gauge pneumograph placed around the abdomen (Pneumotrace, UFI, Morro Bay, CA, USA) to avoid potential confound of large respiratory excursions on cardiovascular measurements during handgrip and PEI. Insulin was measured via an EIA assay (ALPCO, Salem, NH). Insulin resistance was assessed using the homeostatic model assessment of insulin resistance (HOMA-IR): HOMA-IR = (glucose X insulin) / 22.5.

Muscle Sympathetic Nerve Activity. Multiunit postganglionic MSNA was recorded using standard microneurographic techniques, as previously described (13, 36, 53, 54). Briefly, a tungsten microelectrode was placed into the peroneal nerve near the left fibular head, and a reference microelectrode was inserted 2-3 cm away. Signals were amplified, filtered (bandwidth 0.7-2.0 kHz), rectified and integrated (0.1 s time constant) to obtain mean voltage neurograms using a nerve traffic analyzer (Nerve Traffic analyzer, model 662c-3; University of Iowa Bioengineering, Iowa City, IA). MSNA was identified by the presence of spontaneous pulse synchronous bursts that were responsive to end-expiratory breath holds, but not to arousal or stroking of the skin. Although MSNA signals were obtained in all control subjects, 1 normotensive and 1 hypertensive T2D patient were highly sensitive to the procedure so it was stopped, and we were unable to attain quality signals in 2 others (1 normotensive and 1
hypertensive T2D patient). All neural cardiovascular data was acquired at a frequency of 1,000 Hz using Chart version 5.2 (Powerlab, ADInstruments, Bella Vista, NSW, Australia).

Isometric handgrip. Subjects were seated in a semi-recumbent position with a handgrip dynamometer held in the right hand (model 76618; Lafayette Instrument, Lafayette, IN) with the limb supported on an adjustable bedside table. Maximum voluntary contraction (MVC) was determined as the highest of three to five maximal efforts each separated by 1 min, and was used to calculate relative work rates of 30 and 40% MVC for the experimental protocol. During the experimental protocol, ratings of perceived exertion (RPE) were acquired using the Borg scale of 6 to 20 at the end of each bout of handgrip.

Experimental protocol. All experiments were performed in a dimly-lit room at an ambient room temperature of 22-24°C with external stimuli minimized. On the experimental day, subjects arrived at the laboratory following an overnight fast, and were also requested to abstain from caffeinated beverages for 12 h and strenuous physical activity and alcohol for at least 24 h. T2D patients were also instructed to refrain from all medication use the morning of the study. Before the performance of the experimental protocol, each subject was familiarized with all measurements, the equipment and testing procedures. After instrumentation for all experimental measurements, a 10 min baseline recording was performed to determine resting cardiovascular variables and MSNA. Subjects then performed 2 min of isometric handgrip at either 30% or 40% MVC followed by 2 min and 15 s of forearm ischemia to isolate muscle metaboreflex activation (PEI). PEI was achieved by inflation of a blood pressure cuff around the upper arm to suprasystolic pressure (>240 mmHg) 5
s before the end of handgrip exercise. The additional 15 s of PEI was included to account for the
initial decrease in BP and MSNA that occurs immediately following the cessation of handgrip
exercise. Visual feedback regarding the handgrip force exerted was provided via a personal
computer displayed at eye level (Chart v5.2, Powerlab). In all cases except one, the 30% MVC
trial was performed first due to the greater probability for muscle tension and loss of the MSNA
signal during 40% MVC handgrip. The handgrip trials were separated by at least 15 min to allow
BP, MSNA, and HR to return to baseline values.

Cold pressor test. A cold pressor test was used to determine BP, MSNA, and HR responses to a
generalized, non-exercise sympatohexcitatory stimulus (55). The right hand was placed in ice
water for 2 min. All variables were recorded during a 2 min baseline period, during the cold
pressor test, and for 2 min during recovery.

Data Analysis. Resting values for BP, MSNA, and HR were calculated as mean values over a 10
min steady-state period. MSNA was analyzed using a custom LabVIEW program (12, 13).
MSNA was quantified as burst frequency (bursts/min), burst incidence (bursts/100 cardiac
cycles) and total activity (burst frequency multiplied by mean burst amplitude; AU/min). To
account for variation in burst amplitude, MSNA burst amplitudes were expressed as a percentage
of the average of the three largest bursts during baseline (assigned a mean value of 100 arbitrary
units; AU). Thirty second averages of handgrip exercise (30-60 s and 90-120 s) and the final 60 s
averages of PEI were used for group comparisons. The first 60 s and second 60 s of the cold
pressor test were averaged and used for group comparisons.
To examine the interaction between the muscle metaboreflex and the arterial baroreflex, spontaneous baroreflex control of MSNA was calculated during PEI and compared to resting measures. Briefly, MSNA was averaged over 3-mmHg diastolic BP ranges (bins), and a weighted linear regression analysis between the spontaneous changes in MSNA and diastolic BP was performed. MSNA within each pressure bin was calculated as total MSNA (total area of all MSNA bursts relative to the number of cardiac cycles) and expressed as AU/beat. Burst incidence within each pressure bin was also calculated. Diastolic BP was used for this analysis because changes in MSNA correlate closely with changes in diastolic BP but not systolic BP (51).

Statistical Analysis. All data are reported as mean ± SEM. Statistical comparisons of resting physiological variables between groups were made using one-way analysis of variance (ANOVA). Statistical comparisons of changes in BP, MSNA, and HR between groups during handgrip and PEI, and during the CPT, were made using two-way repeated measures ANOVA. Bonferonni post hoc testing was applied where significant main effects were found. Pearson product-moment correlation coefficients were performed between metabolic parameters and BP and MSNA responses to handgrip, PEI and the CPT. Data was analyzed using SigmaPlot 13 (Systat Software Inc.).

Results

Subject Characteristics. Age and BMI were not different between Controls and T2D patients (Table 1). As expected, T2D patients had significantly elevated plasma glucose, HbA1c, and
HOMA-IR compared to Control subjects (Table 1). No significant differences in resting systolic, diastolic, or MAP were found between Controls and T2D Patients (Table 1). In this regard, all hypertensive T2D patients were currently on an active treatment regimen (≥ 1 antihypertensive medications) (Table 2). Resting MSNA burst frequency and burst incidence was also not different between Controls and T2D Patients (Table 1). A comparison of normotensive and hypertensive T2D patients demonstrated no significant differences in resting metabolic, cardiovascular or MSNA variables (Table 3). The only significant difference found was a greater BMI in hypertensive T2D patients. MVC was not different between groups (Control: 40 ± 3 kg; T2D: 38 ± 3 kg; T2D+HTN: 42 ± 3 kg; P=0.908).

Isometric handgrip and PEI.

Original recordings of BP and MSNA at baseline, during 30% MVC handgrip, and during PEI in 3 T2D patients and 3 control subjects are displayed in Fig. 1. The increase in MAP was significantly greater during 30% and 40% MVC handgrip in T2D patients compared to control subjects and these augmented pressor responses in T2D patients were maintained during PEI (Fig. 2). Similar results were found with systolic BP (30% MVC, P=0.001 vs. Control; 40% MVC, P=0.011 vs. Control), and diastolic BP (30% MVC, P<0.001 vs. Control; 40% MVC, P=0.021 vs. Control) (data not shown). The increase in HR during handgrip was also significantly greater in T2D patients, but only during 30% MVC handgrip (P<0.001 vs. Control), and returned toward baseline values during PEI following both 30% and 40% handgrip in both T2D patients and controls (Figure 2). RPE values obtained at the end of handgrip were not different between groups (30% MVC: T2D, 13.5 ± 0.6 vs. Control, 11.8 ± 0.6, P=0.057; 40% MVC: T2D, 15.7 ± 0.5 vs. Control, 14.3 ± 0.8, P=0.161).
MSNA responses to handgrip and PEI were also significantly greater in T2D patients compared to controls (Fig. 3). In this regard, during handgrip exercise at 30% MVC, the change in MSNA burst frequency and percent change in total activity was augmented in T2D patients compared to controls, and this augmented MSNA response was sustained during PEI (Fig 3A). Likewise, MSNA burst incidence was greater in T2D patients during 30% MVC handgrip and PEI (HG 120: T2D, Δ20.1 ± 3.8 vs. Control, Δ6.5 ± 1.7 burst/100 heartbeats, P<0.001; PEI: T2D, Δ23.8 ± 6.5 vs. Control, Δ9.9 ± 2.5 burst/100 heartbeats, P<0.001). During handgrip and PEI at 40% MVC, the percent change in MSNA total activity was also augmented in T2D patients; whereas, the change in MSNA burst frequency did not reach statistical significance, although there was a tendency for a greater response in T2D patients (Fig. 3B, top panel). The latter may be due to maintaining MSNA recordings in only 8 T2D patients during 40% MVC handgrip. This was primarily due to muscle tension and loss of the MSNA signal with this higher intensity of handgrip. In contrast, quality MSNA recordings were maintained during 30% MVC handgrip and PEI in 12 T2D patients. Nevertheless, MSNA burst incidence was greater in the T2D patients during 40% MVC handgrip and PEI (HG 120: T2D, Δ27.4 ± 6.1 vs. Control, Δ13.0 ± 5.6 burst/100 heartbeats; PEI: T2D, Δ31.7 ± 4.9 vs. Control, Δ16.7 ± 3.6 burst/100 heartbeats, P=0.04).

Among the T2D patients, BP and MSNA responses to isometric handgrip at 30% MVC were similar between those with and without hypertension. Likewise, BP responses to 40% MVC handgrip were not different between normotensive and hypertensive T2D patients, whereas the MSNA response to 40% MVC handgrip was greater in hypertensive T2D patients. Nevertheless, BP and MSNA responses during PEI following both 30% and 40% MVC were not different between normotensive and hypertensive T2D patients (Fig 4). We also tested for
potential sex differences in cardiovascular responses to handgrip and PEI, since our groups were composed of both men and women. We found no effect of sex on any of the variables of interest both during handgrip and PEI. For example, in the control group (N=5 men and 5 women), the increase in MSNA during PEI following 30% MVC handgrip was $\Delta 5.2 \pm 1.5$ bursts/min in the men and $\Delta 6.4 \pm 2.6$ bursts/min in the women ($P=0.702$) and in the T2D patients (N=6 men and 6 women), the increase in MSNA during PEI was $\Delta17 \pm 5.4$ bursts/min in the men and $\Delta14.5 \pm 3.1$ burst/min in the women ($P=0.615$).

The increases in MSNA total activity during PEI following both 30% MVC and 40% MVC handgrip were significantly correlated with fasting glucose, HbA1c, and HOMA-IR (Figure 5). In contrast, weaker relationships between fasting insulin and MSNA responses during PEI were found (30% MVC PEI: $R=0.2$, $P=0.417$; 40% MVC PEI: $R=0.4$, $P=0.153$).

Spontaneous baroreflex control of MSNA at rest was not different between T2D patients and controls for either burst incidence or total MSNA (burst incidence: T2D, -4.7 $\pm$ 0.4 vs. Control, -4.3 $\pm$ 0.5 bursts·100hb$^{-1}$·mmHg$^{-1}$, $P=0.534$; total MSNA: T2D, -2.5 $\pm$ 0.2 vs. Control, -2.5 $\pm$ 0.3 AU·beat$^{-1}$·mmHg$^{-1}$, $P=0.936$). Likewise, the increase in total MSNA gain during PEI was not different between groups (30% MVC PEI: T2D, -3.4 $\pm$ 0.6 vs. Control, -4.4 $\pm$ 0.3 AU·beat$^{-1}$·mmHg$^{-1}$, $P=0.323$).

Cold pressor test. Although the increase in MAP during the cold pressor test appeared to be greater in T2D patients (n=9) compared to control subjects (n=9), this did not reach statistical significance (Fig. 6). However, the change in MSNA burst frequency (Fig 6B) and MSNA total activity (CPT min 2: T2D, 151 $\pm$ 20 vs. Control, 55 $\pm$ 21 %AU/min, $P=0.005$) were significantly greater in T2D patients (n=7) compared to control subjects (n=9). HR responses to the cold
pressor test were not different between groups (CPT min 2: T2D, Δ6 ± 3 vs. Control, Δ3 ± 2 bpm, P=0.330).

For the CPT, significant correlations were noted between increases in MSNA and fasting glucose (R=0.55, P=0.027) and HOMA-IR (R=0.79, P=0.001), but not HbA1c (R=0.39, P=0.134) or fasting insulin (R=0.35, P=0.218). Interestingly, no significant correlations were observed between the increases in MSNA during the CPT and during PEI following 30% MVC (R=0.368, P=0.161) or 40% MVC (R=0.472, P=0.103).

Discussion

The major and novel finding of the present study is that T2D patients exhibit a heightened activation of the metabolic component of the EPR. Indeed, augmented pressor and MSNA responses during handgrip were maintained during isolation of the muscle metaboreflex with PEI. Thus, greater MSNA and BP responses remained in T2D patients when input from central command and the muscle mechanoreflex were removed. Notably, MSNA responses were also greater in T2D patients compared to controls during the CPT. Collectively, these findings indicate, for the first time, that the metabolic component of the EPR is augmented with T2D and this contributes, in part, to augmented pressor and sympathetic responses to exercise in T2D patients. Greater MSNA responses to a generalized non-exercise sympatho-excitatory stimulus such as the CPT suggest that a heightened central sympathetic reactivity may be involved.

Given the fairly well-documented augmentation in exercise BP in T2D patients (23, 25, 38, 39, 43, 44), it was surprising that few studies have attempted to examine potential alterations in the underlying neural cardiovascular mechanisms in this patient group. Furthermore, to our knowledge, no studies have measured MSNA responses during exercise in T2D patients. Given
the significance of the muscle metaboreflex to the pressor response to exercise, we chose to begin with the muscle metaboreflex. To this end, graded PEI was used to trap local metabolites produced by active skeletal muscle and preserve activation of metabosensitive afferent nerve endings, and therefore isolate the metabolic component of the EPR (2, 30). We now demonstrate that PEI following 30 and 40% MVC handgrip resulted in augmented pressor responses, and that these augmented pressor responses were accompanied by enhanced increases in MSNA. Interestingly, the increase in MSNA during PEI was significantly correlated with glucose control and insulin resistance markers (i.e., fasting glucose, HbA1c, and HOMA-IR), implying that the effectiveness of T2D control may play a role (see Figure 5). Indeed, the higher the fasting glucose and HbA1c and the greater level of insulin resistance, the greater augmentation in muscle metaboreflex activation. Taken together, our results suggest that the effects of T2D on the regulatory mechanisms underlying the neural cardiovascular responses to exercise involve at least a heightened metabolic component of the EPR that appears to be related to the severity of T2D.

T2D is commonly associated with hypertension (1, 3, 49, 50), and indeed, a significant number of T2D patients recruited for the present study had hypertension. Given that both human and animal studies have suggested an exaggerated activation of the muscle metaboreflex in hypertension (9, 34, 40, 41), we compared responses between normotensive and hypertensive T2D patients to test if the co-existence of hypertension and T2D would further augment the pressor and MSNA responses to PEI. However, we found that the heightened metaboreflex activation observed in the T2D patients was unaffected by hypertensive status (see figure 4). Both the BP and MSNA responses to handgrip and PEI were similar between normotensive and hypertensive T2D patients. Nonetheless, it is important to note that our data are only reflective of
hypertensive T2D patients that have well controlled BP and it is possible that uncontrolled
hypertensive T2D patients or never treated hypertensive T2D patients might have different
responses. Additional studies are warranted in this regard to further understand the influence of
uncontrolled hypertension among T2D patients on muscle metaboreflex activation.

The mechanisms responsible for the exaggerated muscle metaboreflex activation in T2D
are not entirely clear. Although elevations in BP and MSNA during muscle metaboreflex
activation are primarily driven by the muscle metaboreflex, there is an interaction between the
metaboreflex and the arterial baroreflex that can modify such responses. Indeed, studies have
shown exaggerated neural cardiovascular responses when input from the arterial baroreflex is
removed (48, 56). Likewise, in healthy humans, an increase in the baroreflex control of MSNA
has been observed during isolation of the muscle metaboreflex with PEI (8, 20, 22). Since
previous work suggests that the sensitivity of the arterial baroreflex may be impaired in
conditions associated with T2D such as obesity (6, 16) and hypertension (17, 31), we examined
the interaction between the muscle metaboreflex and the arterial baroreflex. Our findings suggest
that an impaired baroreflex control of MSNA does not appear to contribute to the augmented
MSNA and BP responses observed during PEI since both groups exhibited an increase in MSNA
baroreflex sensitivity with PEI, similar to previous studies (8, 20, 22). However, since only
spontaneous baroreflex measures were used, additional studies are needed to more fully
characterize arterial baroreflex function. It also remains possible that the group IV afferent fibers
in the skeletal muscle interstitium that are responsive to changes in metabolic concentrations
have greater sensitivity in T2D. Alternatively, although handgrip strength and perceived exertion
were not different between T2D patients and control subjects, it remains possible that T2D
patients experience greater metabolite build-up within the muscle interstitium during handgrip.
In this regard, previous work suggests altered skeletal muscle metabolism in T2D patients (4, 42), which may lead to greater production of substances during muscle contraction that stimulate skeletal muscle afferents and contribute to greater metaboreflex activation in T2D patients. Identification of the particular substances responsible for stimulating muscle afferent remains an ongoing area of research (24), and future studies would be needed to characterize the responsiveness of skeletal muscle afferents to various substances in T2D, likely including animal investigations.

In the present study, a CPT was used as a generalized sympathoexcitatory stimulus to assess whether a heightened central sympathetic activation may be augmented in T2D patients. Interestingly, the MSNA responses to the CPT were greater in T2D patients, and there was also a trend for a greater pressor response but this did not reach statistical significance. These results suggest that heightened sympathetic responsiveness in T2D may be global and not specific to metaboreflex activation. However, when MSNA responses to the CPT were compared to MSNA responses to isolated metaboreflex activation, no significant correlations were found. Also, correlations between metabolic measures (fasting glucose, HbA1c, and HOMA-IR) and the MSNA responses to the cold pressor test were noticeably weaker than was seen with isolated metaboreflex activation. Although not determining causality or lack thereof, these data suggest that greater central sympathetic activation may not completely account for the augmented metaboreflex activation of MSNA observed in T2D patients. Nevertheless, further studies are warranted to investigate the mechanism(s) responsible for the heightened BP and MSNA mediated metaboreflex responses in T2D as well as hypertension and will likely require animal investigations to tease apart the afferent, central and efferent pathways.
Perspectives

Exaggerated increases in exercise BP are related to adverse cardiovascular and cerebrovascular events both during and following exercise (19, 27, 33). Although it is known that T2D patients exhibit augmented BP responses to exercise, limited studies have focused on the sympathetic and cardiovascular responses to isometric exercise in this patient group. This is important because isometric contractions are a component of many daily activities, and are capable of inducing marked increases in BP and afterload on the heart even when performed with a small muscle mass (32). This highlights the significance of the augmented increases in BP and MSNA that were observed in T2D patients and attributable in part to a heightened muscle metaboreflex activation. These findings are of vital importance given the incidence of myocardial infarction and stroke among T2D patients (5, 26, 28, 57), and the number of common daily activities that involve an isometric muscle contraction component. Given our findings of a significant contribution of the muscle metaboreflex to greater pressor and sympathetic responses to isometric contractions in patients with T2D, future studies to identify the mechanism(s) responsible to target and reduce such hyper-responses are needed. In the meantime, if prescribed to a T2D patient for better health and fitness, resistance exercise training should be prescribed at a low intensity and duration for this patient population.

In summary, we report for the first time that greater pressor responses in T2D during isometric handgrip are attributable, in part, to heightened muscle metaboreflex activation. Augmented pressor responses to handgrip and PEI in T2D patients are paralleled by exaggerated increases in MSNA. These findings demonstrate that the metabolic component of the EPR is augmented in T2D, and provide important insight to the neural mechanisms that contribute to the exaggerated increases in exercise BP in T2D.
Grants

This research was supported by an American Heart Association Grant in Aid (20160072 to P.J.F.), by a Mizzou Advantage Grant (to P.J.F.) and by an ACSM Foundation Research Grant from the American College of Sports Medicine Foundation (S.W.H.). The results of the study do not constitute endorsement by ACSM.

Disclosures

No conflicts of interest, financial or otherwise, are declared by the authors.

Author Contributions

Author contributions: S.W.H., J.P.F., and P.J.F. conception and design of research; C.M., and G.L. assisted with patient recruitment and screening; S.W.H., R.M.R., J.P.F., and P.J.F. performed experiments; S.W.H. analyzed data and prepared figures; S.W.H., J.P.F., and P.J.F. interpreted results of experiments; S.W.H drafted manuscript; S.W.H., C.M., J.P.F., and P.J.F. edited and revised the manuscript; S.W.H., R.M.R., C.M., G.L., J.P.F., and P.J.F. approved the final version of the manuscript.

Acknowledgements

We thank Charla Jay, R.N., for assistance with screening blood draws and patient recruitment. We also would like to thank Joseph W. LeMaster, M.D., and Colin N. Young, PhD for assistance
during the initiation of these studies. This research was submitted in partial fulfilment of the
requirements for the degree of Doctor of Philosophy for Seth W. Holwerda.
References


Figure 1. Original recordings of muscle sympathetic nerve activity (MSNA) and mean arterial pressure (MAP) in 3 type 2 diabetic patients (T2D; Panels A-C) and 3 control subjects (Panels D-F) at baseline, during 30% MVC isometric handgrip, and during post-exercise ischemia (PEI).

Figure 2. Mean and individual data showing the change in mean arterial pressure (MAP) and heart rate (HR) at 60 and 120 s of 30% MVC (Panel A) and 40% MVC (Panel B) handgrip followed by subsequent periods of post-exercise ischemia (PEI) in type 2 diabetic patients (T2D) and control subjects.*P<0.05 vs. Control.

Figure 3. Mean and individual data showing the change in muscle sympathetic nerve activity (MSNA) at 60 and 120 s of 30% MVC (Panel A) and 40% MVC (Panel B) handgrip followed by subsequent periods of post-exercise ischemia (PEI) in type 2 diabetic patients (T2D) and control subjects.*P<0.05 vs. Control.

Figure 4. Mean summary data showing the changes in mean arterial pressure (MAP) and muscle sympathetic nerve activity (MSNA) during isolation of the muscle metaboreflex with post-exercise ischemia (PEI) following 30% maximal voluntary contraction (MVC) handgrip (Panel A) and 40% MVC handgrip (Panel B) in normotensive (T2D+NTN) and hypertensive type 2 diabetic patients (T2D+HTN).

Figure 5. Correlations between the change in muscle sympathetic nerve activity (MSNA) during post-exercise ischemia (PEI) following 30% maximal voluntary contraction (MVC) handgrip (Panel A) and 40% MVC handgrip (Panel B) and fasting glucose, glycated hemoglobin (HbA1c), and homeostatic model assessment of insulin resistance (HOMA-IR) in all subjects.

Figure 6. Mean summary data showing the change in mean arterial pressure (MAP; Panel A) and muscle sympathetic nerve activity (MSNA; Panel B) at 60 and 120 s of a cold pressor test in type 2 diabetic patients (T2D) and control subjects.*P<0.05 vs. Control.
Table 1. Main subject characteristics

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>T2D</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, men/women</td>
<td>5/5</td>
<td>9/7</td>
<td>0.334</td>
</tr>
<tr>
<td>Age, years</td>
<td>46 ± 3</td>
<td>50 ± 2</td>
<td>0.312</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29 ± 2</td>
<td>31 ± 4</td>
<td>0.312</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>95 ± 2</td>
<td>198 ± 22*</td>
<td>0.001</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>5.3 ± 0.1</td>
<td>8.6 ± 0.5*</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Insulin (μIU/mL)</td>
<td>7.6 ± 0.7</td>
<td>11 ± 2.3</td>
<td>0.293</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.8 ± 0.2</td>
<td>4.6 ± 0.7*</td>
<td>0.013</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>114 ± 20</td>
<td>184 ± 38</td>
<td>0.172</td>
</tr>
</tbody>
</table>

Cardiovascular variables

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (bpm)</td>
<td>63 ± 4</td>
<td>69 ± 3</td>
<td>0.212</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>122 ± 4</td>
<td>128 ± 4</td>
<td>0.313</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>78 ± 2</td>
<td>81 ± 3</td>
<td>0.394</td>
</tr>
<tr>
<td>Mean BP (mmHg)</td>
<td>91 ± 3</td>
<td>97 ± 3</td>
<td>0.258</td>
</tr>
</tbody>
</table>

MSNA

<table>
<thead>
<tr>
<th></th>
<th>N=10</th>
<th>N=12</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Burst frequency (burst/min)</td>
<td>25 ± 4</td>
<td>31 ± 2</td>
<td>0.230</td>
</tr>
<tr>
<td>Burst incidence (burst/100hb)</td>
<td>39 ± 6</td>
<td>46 ± 4</td>
<td>0.361</td>
</tr>
<tr>
<td>Total activity (AU/min)</td>
<td>1241 ± 219</td>
<td>1411 ± 139</td>
<td>0.520</td>
</tr>
</tbody>
</table>

*P<0.05 vs. Control
<table>
<thead>
<tr>
<th>Table 2. Subject medications</th>
<th>Control</th>
<th>T2D+NTN</th>
<th>T2D+HTN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypoglycemic medications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biguanide</td>
<td>N=0</td>
<td>N=5</td>
<td>N=7</td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>N=0</td>
<td>N=1</td>
<td>N=0</td>
</tr>
<tr>
<td>DPP-4 inhibitor</td>
<td>N=0</td>
<td>N=0</td>
<td>N=3</td>
</tr>
<tr>
<td>Insulin</td>
<td>N=0</td>
<td>N=2</td>
<td>N=4</td>
</tr>
<tr>
<td><strong>Cardiovascular medications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>N=0</td>
<td>N=0</td>
<td>N=5</td>
</tr>
<tr>
<td>Ang II receptor blocker</td>
<td>N=0</td>
<td>N=0</td>
<td>N=1</td>
</tr>
<tr>
<td>Diuretic</td>
<td>N=0</td>
<td>N=0</td>
<td>N=4</td>
</tr>
<tr>
<td>β-blocker</td>
<td>N=0</td>
<td>N=0</td>
<td>N=1</td>
</tr>
<tr>
<td>Statin</td>
<td>N=0</td>
<td>N=2</td>
<td>N=5</td>
</tr>
<tr>
<td></td>
<td>T2D+NTN</td>
<td>T2D+HTN</td>
<td>P value</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Sex, men/women</td>
<td>4/4</td>
<td>5/3</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>48 ± 4</td>
<td>51 ± 2</td>
<td>0.576</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29 ± 2</td>
<td>34 ± 1†</td>
<td>0.032</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>209 ± 34</td>
<td>187 ± 29</td>
<td></td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>8.8 ± 0.8</td>
<td>8.5 ± 0.7</td>
<td>0.797</td>
</tr>
<tr>
<td>Insulin (µIU/mL)</td>
<td>11.4 ± 4.9</td>
<td>10.8 ± 1.5</td>
<td>0.904</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>4.5 ± 1.3</td>
<td>4.8 ± 0.8</td>
<td>0.860</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>175 ± 44</td>
<td>92 ± 64</td>
<td>0.833</td>
</tr>
<tr>
<td>Cardiovascular variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>69 ± 3</td>
<td>68 ± 4</td>
<td>0.890</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>126 ± 6</td>
<td>130 ± 5</td>
<td>0.551</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>80 ± 4</td>
<td>83 ± 5</td>
<td>0.604</td>
</tr>
<tr>
<td>Mean BP (mmHg)</td>
<td>95 ± 4</td>
<td>99 ± 5</td>
<td>0.568</td>
</tr>
<tr>
<td>MSNA</td>
<td>N=6</td>
<td>N=6</td>
<td></td>
</tr>
<tr>
<td>Burst frequency (burst/min)</td>
<td>31 ± 3</td>
<td>31 ± 3</td>
<td>0.980</td>
</tr>
<tr>
<td>Burst incidence (burst/100hb)</td>
<td>46 ± 5</td>
<td>45 ± 7</td>
<td>0.955</td>
</tr>
<tr>
<td>Total activity (AU/min)</td>
<td>1382 ± 209</td>
<td>1439 ± 201</td>
<td>0.846</td>
</tr>
</tbody>
</table>

†P<0.05 vs. T2D+NTN
Figure 1

A) T2D patient 1

MAP (mmHg)

80 100 120

Integrated MSNA

B) T2D patient 2

MAP (mmHg)

80 100 120

Integrated MSNA

C) T2D patient 3

MAP (mmHg)

80 100 120

Integrated MSNA

Baseline Isometric handgrip Post-exercise ischemia

D) Control 1

MAP (mmHg)

80 100 120

Integrated MSNA

E) Control 2

MAP (mmHg)

80 100 120

Integrated MSNA

F) Control 3

MAP (mmHg)

80 100 120

Integrated MSNA

Baseline Isometric handgrip Post-exercise ischemia
Figure 2

A) 30% MVC

- ΔMAP (mmHg)
- HG 60, HG 120, PEI
- Control
- T2D

Group: P<0.001
Time point: P<0.001
Interaction: P<0.001

B) 40% MVC

- ΔMAP (mmHg)
- HG 60, HG 120, PEI
- Control
- T2D

Group: P=0.009
Time point: P<0.001
Interaction: P=0.008

- ΔHR (bpm)
- HG 60, HG 120, PEI

Group: P=0.042
Time point: P<0.001
Interaction: P=0.039

Group: P=0.649
Time point: P<0.001
Interaction: P=0.790
Figure 3

A) 30% MVC

- Group: P=0.002
- Time point: P<0.001
- Interaction: P=0.001

B) 40% MVC

- Group: P=0.059
- Time point: P<0.001
- Interaction: P=0.081
Figure 4

A) 30% MVC PEI

B) 40% MVC PEI

P-values for each comparison:
P = 0.886
P = 0.928
P = 0.828
P = 0.201
P = 0.204
P = 0.691
P = 0.915
P = 0.341
Figure 6

A)  
\[ \Delta \text{MAP (mmHg)} \]

- \text{Control}  
- \text{T2D}

- Group: \( P = 0.080 \)
- Time point: \( P < 0.001 \)
- Interaction: \( P = 0.094 \)

B)  
\[ \Delta \text{MSNA (bursts/min)} \]

- Group: \( P = 0.002 \)
- Time point: \( P < 0.001 \)
- Interaction: \( P = 0.002 \)

- \( 60 \text{ s} \)
- \( 120 \text{ s} \)

* indicates statistical significance at the 0.05 level.